Recent advances in acute promyelocytic leukaemia

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Acute promyelocytic leukaemia (APML) is a distinct subtype of leukaemia.
• It is characterized by a specific chromosomal translocation t(15;17) leading to the PML-RARA fusion gene.
• Historically, APML had a poor prognosis.

Purpose of the Study:

• To review the historical transformation of APML treatment.
• To highlight the impact of novel therapeutic agents.
• To discuss recent advances in APML management.

Main Methods:

• Literature review of APML treatment strategies over the past three decades.
• Analysis of the efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).
• Exploration of the development of targeted cancer therapies.

Main Results:

• APML has transitioned from a highly fatal disease to a highly curable condition.
• The introduction of ATRA and ATO has revolutionized APML treatment outcomes.
• These advancements represent a paradigm shift towards genetically targeted cancer therapy.

Conclusions:

• The treatment journey of APML exemplifies successful targeted therapy development.
• Current management strategies offer high cure rates for APML patients.
• Ongoing research continues to refine APML treatment and management.